These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31468659)

  • 1. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.
    Koomen JV; Heerspink HJL; Schrieks IC; Schwartz GG; Lincoff AM; Nicholls SJ; Svensson A; Wedel H; Weichert A; Grobbee DE; Stevens J
    Diabetes Obes Metab; 2020 Jan; 22(1):30-38. PubMed ID: 31468659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
    Henry RR; Lincoff AM; Mudaliar S; Rabbia M; Chognot C; Herz M
    Lancet; 2009 Jul; 374(9684):126-35. PubMed ID: 19515415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
    Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
    JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
    Lincoff AM; Tardif JC; Neal B; Nicholls SJ; Rydén L; Schwartz GG; Malmberg K; Buse JB; Henry RR; Wedel H; Weichert A; Cannata R; Grobbee DE
    Am Heart J; 2013 Sep; 166(3):429-34. PubMed ID: 24016490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
    Erdmann E; Califf R; Gerstein HC; Malmberg K; Ruilope L; Schwartz GG; Wedel H; Volz D; Ditmarsch M; Svensson A; Bengus M
    Am Heart J; 2015 Jul; 170(1):117-22. PubMed ID: 26093872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
    Han CL; Qu CZ
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):351-357. PubMed ID: 31929323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.
    Younk LM; Uhl L; Davis SN
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):753-63. PubMed ID: 21521130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
    Ruilope L; Hanefeld M; Lincoff AM; Viberti G; Meyer-Reigner S; Mudie N; Wieczorek Kirk D; Malmberg K; Herz M
    BMC Nephrol; 2014 Nov; 15():180. PubMed ID: 25407798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
    Stirban AO; Andjelkovic M; Heise T; Nosek L; Fischer A; Gastaldelli A; Herz M
    Diabetes Obes Metab; 2016 Jul; 18(7):711-5. PubMed ID: 26663152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.
    Sanwald-Ducray P; Liogier D'ardhuy X; Jamois C; Banken L
    Clin Pharmacol Ther; 2010 Aug; 88(2):197-203. PubMed ID: 20336066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
    Sturm S; Seiberling M; Weick I; Paehler A; Funk C; Ruf T
    Clin Ther; 2012 Feb; 34(2):420-9. PubMed ID: 22244809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No evidence of QT prolongation with supratherapeutic doses of aleglitazar.
    Sturm S; Bentley D; Jordan P; Russell-Yarde F; Ruf T
    J Cardiovasc Pharmacol; 2012 Mar; 59(3):288-97. PubMed ID: 22113345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
    Foley-Comer AJ; Young AM; Russell-Yarde F; Jordan P
    Expert Opin Investig Drugs; 2011 Jan; 20(1):3-12. PubMed ID: 21114416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects.
    Sanwald-Ducray P; Jamois C; Banken L
    J Cardiovasc Pharmacol; 2014 Feb; 63(2):152-7. PubMed ID: 24157957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
    Chen Y; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y; Qian J
    Diab Vasc Dis Res; 2017 Mar; 14(2):152-162. PubMed ID: 28111985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
    Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
    Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
    Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
    Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.
    Herz M; Gaspari F; Perico N; Viberti G; Urbanowska T; Rabbia M; Wieczorek Kirk D
    Int J Cardiol; 2011 Sep; 151(2):136-42. PubMed ID: 20837369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.